Sentence examples for more expensive biologic from inspiring English sources

The proportions of direct and indirect costs of lost productivity may be shifting towards direct costs, as more expensive biologic medications are being increasingly used.

If we educate patients with RA on risks to the fetus, importance of folic acid, and alcohol-related liver toxicity, they may be more likely to comply with the medication regimen, its use will be safer, and society will save money, as patients may avoid having to move onto more expensive biologic use and have improved disease activity, greater function, and less work loss.

Increasingly, Americans are taking more expensive biologics beyond pills and capsules and they require specialty pharmacies to dispense them, working with an array of providers, particularly for an aging population in assisted living and long-term care facilities.

If successful, these small compounds could augment or replace more expensive parenteral biologics that are currently the mainstay of treatment.

The Dovobet gel strategy allows a 5% reduction in the number of patients who could potentially be treated with more expensive therapies (biologics and conventional systemic drugs) in comparison with the Dovobet ointment strategy, with a consequent impact on costs for the National Healthcare Service.

The ability to process large numbers of chemicals to predict inactivity for ER binding and to categorically prioritize the remainder provides one biologic measure to prioritize chemicals for entry into more expensive assays (most chemicals have no biologic data of any kind).

Although biologics are more expensive than other forms of therapy by about US$30,000 per patient per year, 6 they may indirectly lessen costs for some patients by reducing the need, or length of hospitalization, 7 and by increasing productivity and reducing work limitations.

And, they are biologics, which are more expensive to produce than small-molecule drugs.

Biologic drugs can be more expensive to manufacture; they are grown inside living cells rather than put together chemically, as conventional drugs are.

The value of equity is particularly critical within the context of disease-specific stem-cell therapies, given that they are highly specialized biologics which tend to be much more expensive than standard primary care services.

With the introduction of biologics the question arises of whether these – far more expensive – drugs are more effective than synthetic DMARDs.